Kamada Ltd. develops, produces and markets plasma-derived protein therapies for orphan indications. The company is headquartered in Rehovot, Israel.
| Revenue (TTM) | $181.68M |
| Gross Profit (TTM) | $74.77M |
| EBITDA | $38.91M |
| Operating Margin | 15.40% |
| Return on Equity | 7.97% |
| Return on Assets | 4.19% |
| Revenue/Share (TTM) | $3.12 |
| Book Value | $4.50 |
| Price-to-Book | 1.66 |
| Price-to-Sales (TTM) | 2.37 |
| EV/Revenue | 1.987 |
| EV/EBITDA | 9.44 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 2.80% |
| Shares Outstanding | $57.69M |
| Float | $9.37M |
| % Insiders | 7.20% |
| % Institutions | 48.54% |
Volatility is currently contracting